Teva Pharmaceutical Industries (TEVA) Q3 FY2026 earnings: revenue $4.4 billion, down 1.9% on the year
Teva Pharmaceutical Industries Ltd. (TEVA) reported revenue of $4.4 billion for Q3 FY2026, the quarter ended 30 September 2026, down 1.9% on the same quarter a year earlier. Net income was $233 million, down 46.2% on the year, and diluted earnings per share $0.20. The figures are the company's own, from the 10-Q it filed with the SEC on 3 November 2026.
Revenue
$4.4 billion
-1.9% on the year · +6.1% on the quarter
Q4 FY2024Q3 FY2026
Operating margin
16.2%
19.7% a year earlier
Q4 FY2024Q3 FY2026
Net income
$233 million
-46.2% on the year
Q4 FY2024Q3 FY2026
Diluted EPS
$0.20
-45.9% on the year
Q4 FY2024Q3 FY2026
this quarterthe same quarter a year earlierHover a bar for its figure.
Revenue fell 2% year-over-year: Revenues were $4,395 million, down 2% in U.S. dollars and local currency from $4,480 million, mainly on lower lenalidomide capsule revenue, partly offset by AUSTEDO, AJOVY and UZEDY.
Non-GAAP diluted EPS rose 10%: Non-GAAP diluted EPS was $0.86, up from $0.78, and includes $0.02 of acquired IPR&D charges. GAAP diluted EPS was $0.20, down from $0.37.
US revenue down 11%: US segment revenue was $1,870 million, down 11%, and segment profit was $791 million versus $927 million. US generic products revenue fell 39% to $718 million.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Operating cash flow
241
411
369
-41.4%
-34.7%
Capital expenditure
120
104
136
+15.4%
-11.8%
Free cash flow
121
307
233
-60.6%
-48.1%
Free cash flow margin
2.8%
7.4%
5.2%
Cash from investing
210
-491
135
+55.6%
Cash from financing
6.0
-1.0
-453
Depreciation and amortisation
245
241
249
+1.7%
-1.6%
Share-based compensation
38.0
40.0
34.0
-5.0%
+11.8%
Diluted shares, weighted
1,183m
1,165m
1,164m
+1.5%
+1.6%
Shares outstanding at period end
1,167m
1,165m
1,147m
+0.1%
+1.7%
Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.
Balance sheet
$ million
Q3 FY2026
Q2 FY2026
Q3 FY2025
On the quarter
On the year
Last 8 quarters
Shareholders' equity
7,979
7,753
7,250
+2.9%
+10.1%
Non-controlling interest
5.0
4.0
4.0
+25.0%
+25.0%
Redeemable equity
n/a
n/a
0.0
Debt
16,718
16,592
16,790
+0.8%
-0.4%
Operating lease liabilities
266
282
283
-5.7%
-6.0%
Other liabilities
15,074
15,226
15,529
-1.0%
-2.9%
Total liabilities and equity
40,042
39,857
39,856
+0.5%
+0.5%
Fixed assets
3,747
3,928
4,820
-4.6%
-22.3%
Goodwill
15,742
15,839
15,945
-0.6%
-1.3%
Intangible assets
3,303
3,447
3,936
-4.2%
-16.1%
Cash and equivalents
4,085
3,655
2,203
+11.8%
+85.4%
Receivables
3,837
3,493
3,810
+9.8%
+0.7%
Inventory
3,173
3,221
3,323
-1.5%
-4.5%
Other assets
6,155
6,274
5,819
-1.9%
+5.8%
Total assets
40,042
39,857
39,856
+0.5%
+0.5%
Questions
What was Teva Pharmaceutical Industries' revenue in Q3 FY2026?
Teva Pharmaceutical Industries (TEVA) reported revenue of $4.4 billion for Q3 FY2026, the quarter ended 30 September 2026, down 1.9% on the same quarter a year earlier.
How much did Teva Pharmaceutical Industries earn in Q3 FY2026?
Net income for Q3 FY2026 was $233 million, down 46.2% on the year, and diluted earnings per share $0.20.
When did Teva Pharmaceutical Industries report Q3 FY2026 results?
Teva Pharmaceutical Industries filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 3 November 2026.
Each quarter as filed, linked to its filing. Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.
10-Q for the period ended 30 September 2026, filed 3 November 2026: the filing.